I. ABSTRACT
II. INTRODUCTION

During the last years, a separate subset of T helper cells, named follicular T helper cells (T FH )
has been extensively described (for review, see [1] [2] [3] ). T FH cells are characterized by their homing capacities in the GC of B-cell follicles where they interact with B cells, supporting Bcell survival and antibody responses. T FH cells are characterized by a gene expression signature distinct from that of other T-cell subsets [4] , and they can be identified by an array of markers including the chemokine CXCL13, the co-stimulatory molecules ICOS, PD1, and the transcription factor BCL6 used by flow cytometry and/or immunohistochemistry on routinely fixed biopsies. These markers appear to be relevant for the diagnosis of angioimmunoblastic T-cell lymphoma (AITL) and have helped to recognize subsets of peripheral T-cell lymphoma, NOS with nodal or cutaneous presentation expressing T FH antigens that might be related to AITL. [5, 6] In this review, we will summarize the main characteristics of T FH cells with special attention to the markers useful for their identification, and describe the implications of T FH cells in neoplastic haematopathology, both in T-cell lymphomagenesis or as part of the tumour microenvironment in some B-cell neoplasms. T FH cells is able to upregulate CXCR5, ICOS, PD1, IL-21R, IL-6R (and to downregulate CCR7) . These effects can be antagonized by BLIMP1 which represses BCL6 and is downregulated in T FH cells. To note, the effect of BCL6 on multiple T FH genes appears at least partly mediated by the downregulation of many miRNAs, many of which are predicted to target T FH genes (reviewed in: [10] )
III. FOLLICULAR HELPER T-CELLS
During the last years, T follicular helper (T FH
How to recognize T FH cells in routine practice? -Several markers characteristically expressed by T FH cells can be used in diagnostic practice either by flow cytometry and/or by immunohistochemistry on routinely fixed tissue samples to identify reactive or neoplastic T FH cells. These include the cell surface molecules CXCR5, CD154, PD1, ICOS, CD200, and cytoplasmic SAP (SLAM-associated protein). [11] [12] [13] [14] [15] [16] [17] as well as the transcription factors BCL6 and MAF. [18] [19] [20] CD57 is less specific and is expressed in only a small proportion of T FH cells. [21] In fact, beyond their specific function to provide help to B cell, the precise phenotypic definition of T FH cells remains elusive since most of these T FH markers can individually be expressed by other T cell subsets. Indeed, levels of ICOS or PD1 are found in activated T cells, and T FH cells are best defined by high expression of CXCR5, ICOS, PD1, IL-21 and BCL6 (with low level of TBX21 (T-bet), GATA3, Rort and FOXP3 that characterized Th1, Th2, Th17 and T reg, respectively). Consequently, a combination, and more importantly the amount, of "T FH " markers such as CXCR5, ICOS, PD1, is recommended to identify T FH cells by flow cytometry analysis. [10] On tissue sections, where the possibity of multicolour analysis is limited, the use of several T FH markers has been recommended [22] and attention should be paid to the distribution and intensity of the immunostainings. Among T FH mediators, the chemokine CXCL13 appears quite specific. For diagnostic purposes, CXCL13, PD1, ICOS and BCL6 most likely represent the most useful and robust immunohistochemical T FH markers.
Interestingly, CD10, reported to be a sensitive marker for AITL by immunohistochemistry and/or flow cytometry [11, 19, [23] [24] [25] [26] , has not been identified in the gene signature of normal T FH cells. [4] However, minor populations of CD3+/CD10+ have been detected in normal lymph nodes, or B-cell lymphomas. [27] [28] [29] raising the question whether CD10 could be assigned to a subset of normal T FH cells.
As the development of T FH cells has begun to be better understood, several questions have arisen. There is evidence that T FH cells are heterogeneous comprising at least the GC-T FH cells subset described above and non-GC T FH including CD4+ T cells with a TFH phenotype that interact with B cells outside the germinal centres [10] , and even circulating memory T FH cells [30] that might explain some heterogeneity in the phenotypic profile of T FH cells. It appears also more likely that T FH cells result from a conversion of effector Th cells that acquired T FH cell functions while interacting with B cells rather than they constitute a distinct lineage. [2, 10] Moreover, it is to note that not all follicular T cells are B-cell helper cells as some follicular T cells appear to have a suppressive function. [10, 31] In pathologic situations, T FH cells seem to play an important role in autoimmunity. Their interest is also increased since T FH have been shown to give rise to a significant proportion of peripheral T-cell lymphomas and finally may play important roles in some B-cell lymphomas.
IV. PERIPHERAL T-CELL LYMPHOMAS WITH A T FH
IMMUNOPHENOTYPE
Angioimmunoblastic T-cell lymphoma (AITL)
AITL represents the prototype of T FH -derived lymphoma. Described in the seventies as a dysimmune non neoplastic condition, it has later been recognized as a subtype of peripheral T-cell lymphoma (PTCL), given the demonstration of cytogenetic alterations and clonal Tcell receptor (TCR) gene rearrangements in most instances and the identification of clearly malignant morphologic features in some cases (reviewed in de Leval et al. [32] ). Recently, gene expression studies have demonstrated a T FH signature in AITL [33] [34] [35] and the expression of T FH markers in the neoplastic cells has been confirmed by immunostaining methods. AITL is reported as the second most common PTCL worldwide, but appears more prevalent in Europe (representing 29% of the cases) than in North America or Asia where its estimated prevalence is below 20% in a recent survey. [36, 37] The disease which affects elderly adults [38] is usually characterized by generalized peripheral lymphadenopathy, often with concomitant extranodal disease. It is typically manifested by systemic symptoms (fever, weight loss, skin rash, and arthralgias), and by laboratory testing polyclonal hypergammaglobulinemia and Coombs-positive hemolytic anemia are frequent. Occasional spontaneous remissions are reported. The median survival is <3 years in most studies, but a subset of patients experience long-term survival. [38] In lymph nodes, AITL displays distinctive pathological features that may be categorized according to three overlapping architectural patterns, as decribed by Attygalle et al.. [23] In pattern I, seen least frequently, the lymph node has a partially preserved architecture with hyperplastic follicles with poorly developed mantle zones, and a polymorphous infiltrate into the paracortex comprising more or less inconspicuous neoplastic cells, which tend to distribute around the follicles . [39] . This pattern is the most difficult to diagnose. In pattern II (AITL with depleted follicles), depleted follicles which may have Castleman's-like features are present. In pattern III (AITL without follicles), by far the most frequent, there is a complete effacement of architecture by a diffuse proliferation accompanied with prominent irregular perivascular proliferation of FDCs. [23, 39] These patterns are thought to reflect morphologic evolution of the disease rather than clinical progression [14, 23 , 24, 39] expression. In the latter cases, special attention should be paid to the presence of FDC expansion, cellular atypia and expression of CD10 and T FH markers by the T-cell population and clonality analysis might be useful. [40] In practice, the distinction from THRLBCL and cHL is essential, as the latter represent separate entities requiring distinct clinical management and therapies.
The abundance of B cells, which does not seem to impact the clinical outcome [38, 41] , correlates with the detection of B-cell clonality or oligoclonality. [42, 43] A subset of patients go on to develop an EBV-associated B-cell lymphoproliferation, in most instances an EBV-positive diffuse large B-cell lymphoma, less commonly an EBV-negative B-cell or plasma cell neoplasms. [24 , 44 , 45 ] AITL cases with a high content of epithelioid cells (epithelioid variant of AITL), raise differential diagnosis issues as they can suggest a granulomatous disease or be mistaken for other histiocyte-rich B-and T-cell lymphomas or Hodgkin lymphoma. [40] The neoplastic cells of AITL consist of mature  CD4+CD8-T-cells. [26, 28, 46, 47] Reduced or absent expression of pan-T-cell antigen(s) (most commonly sCD3, CD4, CD7) is frequently observed. Partial expression of CD30 by the neoplastic cells is not unusual. [26] In the majority of cases, coexpression of CD10 is observed in a variable proportion of the neoplastic cells [23, 26, 38, 48] As indicated above, AITL has been recently characterized as the prototype of neoplasm derived from T FH cells; accordingly, AITL neoplastic cells can be recognized by the expression of several markers characteristic although not entirely specific of the T FH cells, including the cytoplasmic chemokine CXCL13, the cell membrane antigens PD1, ICOS, CD200, the adaptator molecule SLAM-associated protein (SAP) or BCL6 (Figure 2E-H) . [11, 12, 13 , 14-19, 29, 49 ] . In addition, CXCR5 is also an excellent T FH marker expressed by AITL cells. [12] This cell surface marker is easily detected by flow cytometry, but may be difficult to demonstrate on fixed paraffin tissue sections. It is particularly useful for the detection of the frequent minimal peripheral blood involvement characterized by an aberrant cell surface immunophenotype (most commonly CD10+ and/or sCD3-or dim) and/or expression of T FH antigens. [50] The identification of AITL in extranodal localizations, such as in bone marrow and skin biopsies, may be difficult because of the scarcity of neoplastic cells, especially in the absence of established diagnosis. Immunohistochemistry for CD10 and T FH markers is helpful to identify the neoplastic elements, and molecular genetic studies may demonstrate clonal TCR rearrangement. [25, 51] In the bone marrow and skin infiltrates, CXCL13 may be more useful than CD10 which also stains the stroma and may be difficult to interpret. However, T FH markers are not entirely specific for AITL as a T FH immunophenotype has also been reported in primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (see below). [6] . [34, 52, 53] , and may also act as autocrine factors (for review see [32] ). CXCL13 may also attract mast cells which are a source of IL6 promoting Th17 differentiation. [54] Perturbations of T-cell subsets may also favor EBV reactivation with expansion of EBV-infected B-immunoblasts, and occasional occurrence of an EBV-associated B-cell lymphoproliferative disorder. M2 macrophages expansion and T reg depletion could contribute to the immunosuppressive microenvironment in AITL and to the neoplastic T FH expansion. [55, 56] Interestingly, it has been recently suggested that the microenvironment has prognostic relevance in AITL and a molecular prognosticator related to the microenvironment signature has been constructed. [35] The molecular alterations underlying the neoplastic transformation of T FH cells remain unknown (reviewed in [57] ). By cytogenetic analysis clonal aberrations -most commonly trisomies of chromosomes 3, 5 and 21, gain of X, and loss of 6q -are detected in up to 90% of the cases (reviewed in [58] ). Chromosomal breakpoints affecting the T-cell receptor (TCR) gene loci appear to be extremely rare. [59] 
Follicular Peripheral T-cell lymphoma
The follicular variant of PTCL/NOS named after a pattern of growth intimately related to follicular structures, has been recently described. It comprises cases with a truly follicular pattern, mimicking follicular lymphoma, [60] T-cell lymphomas with a perifollicular growth pattern, [61] or involving expanded mantle zones, therefore mimicking progressive transformation of germinal centres or nodular lymphocyte predominant Hodgkin lymphoma with cellular aggregates of small/medium sized T cells in a background of small IgD+ lymphocytes ( Figure 3A-B) . Neoplastic cells are CD4+ BCL6+ CD10 +/-CD57-, with expression of T FH molecules CXCL13, PD1 and ICOS (Figure 3C-F) . [5, 62] In view of the T FH phenotype, the interaction with B-cells and FDC, and overlapping clinicopathologic features with AITL in some cases [5, 63] , the possible relationship to AITL is questionable.
A recurrent chromosomal translocation t(5;9)(q33;q22) involving ITK and SYK tyrosine kinase, has been described in association with at least some follicular PTCLs, [64] but is otherwise rarely found in non-follicular PTCLs, which may support the concept of a distinct subtype. Interestingly, the fusion tyrosine kinase ITK-SYK has transforming properties in vitro, and induces a T-cell lymphoproliferative disease in mice resembling human PTCL through a signal that mimicks activation of the T cell receptor. [65] [66] [67] In addition, overexpression and activation of SYK appear to be a feature common to most PTCLs, and potentially represents a novel therapeutic target. [68, 69] Other Peripheral T-cell lymphoma, not otherwise specified (PTCL,NOS) expressing T FH markers By definition, PTCL/NOS represents a heterogeneous category of T-cell neoplasms.
However, besides the follicular variant of PTCL/NOS, up to one third of cases classified as PTCL/NOS based on their pathological features, have been found to harbour imprints of traces of the T FH signature and/or to express T FH -associated markers (CXCL13, ICOS, PD1, CD200,..) . [14, 22, 29, 49 ] . Importantly, careful review of the pathological and/or clinical features of these cases have emphasize that at least some of them exhibited other AITL-like features and likely represent AITL evolving into PTCL/NOS-like tumours with a high tumour cell content and partial lost of the characteristic microenvironmental background of fullblown AITL. Thus, a subset of PTCL/NOS cases appears related to or derived from AITL, and the spectrum of AITL may be broader than is currently thought. [33, 48, 57 ] It remains to be defined which criteria should be used to define the borders of AITL entity. In that respect, whether clinical and/or laboratory symptoms should be taken into account in borderline cases requires further investigation.
Cutaneous PTCL expressing T FH markers
Recent studies show that primary cutaneous CD4+ small/medium sized T-cell lymphoma, a provisional entity in the updated WHO classification [70] , may constitute another PTCL subtype with a T FH phenotype, therefore suggesting its derivation from T FH cells [6, 71] Besides, the significance of the observation of cases of mycosis fungoides, which express follicular helper T-cell marker, PD1 is unknown [13] .
V. REACTIVE T FH CELLS IN B-CELL AND HODGKIN LYMPHOMAS
In the past years, there has been increasing interest into the characterization of the presence and distribution of follicular T cells in a variety of B-cell and Hodgkin lymphomas, and several studies have highlighted the usefulness of T FH identification as an adjunct to lymphoma diagnosis. Moreover, there is increasing evidence that the functional implications of T FH cells interacting with neoplastic B cells are biologically relevant, and that T FH -related markers may constitute valid biomarkers of prognosis or response to therapy in certain lymphoma entities. Incidentally, it has been reposted that PD1 is also expressed in the neoplastc B cells of small lymphocytic lymphoma/chronic lymphocytic leukemia, where the expression can be increased by CD40 ligation, while it is not detected in the neoplastic cells of other small B-cell lymphomas. [17, 72] While the biological significance of this findings remains to be clarified, the diagnostic implications are obviously limited.
Diagnosis and differential diagnosis of Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
In nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), a disease entity dictinct [80, 81] . In particular, it has been found in at least two independent cohorts that higher numbers of PD1-positive lymphocytes are associated with improved overall survival in FL patients. [80, 82] Since the prognostic value of high numbers of PD1-positive cells appears to be independent of the classical prognostic index used to stratify FL patients, the abundance of PD1 might be incorporated in the future as a prognostic biomarker of FL. In addition to these observations, functional studies have confirmed the enrichment in T FH cells in the FL microenvironment that display a specific activation profile characterized by the expression of IL-4, that could sustain FL pathogenesis. [83] In classical HL, increased numbers of PD1 positive lymphocytes were found of negative prognostic significance for overall survival, as opposed to the number of FOXP3-positive regulatory T cells [72] . VIII.
